Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372216
Status:
COMPLETED
Last Update Posted:
2010-11-19
First Post:
2006-09-04
Brief Title:
CIPAMI-Study Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction
Sponsor:
Stiftung Institut fuer Herzinfarktforschung
Organization:
Stiftung Institut fuer Herzinfarktforschung
Study Overview
Official Title:
CIPAMI-Study Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acute myocardial infarction is generally caused by a thrombotic occlusion of coronary arteries Primary aim of early therapy is a fast and complete reperfusion of the infarcted myocardium which can be achieved by either thrombolytic therapy or primary PCI
Primary PCI is facilitated if the flow in the target vessel is restored prior to the intervention In addition the results of recent trials hint that clinical outcome is improved by a patent infarct-vessel before primary PCI The CIPAMI-study analyses the effect of an early administration of Clopidogrel on the flow-rates in subjects who suffered an acute myocardial infarction For this purpose they are divided into two groups both receiving standard baseline treatment The subjects of one group additionally receive 600mg of Clopidogrel as early as possible while the subjects in the second group receive standard therapy In the second group Clopidogrel is not allowed before initial angiography
In both groups the flow-rates before and after PCI are analysed and compared in order to evaluate the efficacy feasibility and safety of the administration of a high loading dose Clopidogrel in the very early phase of STEMI in the prehospital setting
Primary PCI is facilitated if the flow in the target vessel is restored prior to the intervention In addition the results of recent trials hint that clinical outcome is improved by a patent infarct-vessel before primary PCI The CIPAMI-study analyses the effect of an early administration of Clopidogrel on the flow-rates in subjects who suffered an acute myocardial infarction For this purpose they are divided into two groups both receiving standard baseline treatment The subjects of one group additionally receive 600mg of Clopidogrel as early as possible while the subjects in the second group receive standard therapy In the second group Clopidogrel is not allowed before initial angiography
In both groups the flow-rates before and after PCI are analysed and compared in order to evaluate the efficacy feasibility and safety of the administration of a high loading dose Clopidogrel in the very early phase of STEMI in the prehospital setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None